JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Park, Naomi
Chi, Jianxiang
Moreno, Thaidy
Abstract
TO THE EDITOR:
The JAK2 V617F mutation is the most common somatic mutation in the classical myeloproliferative neoplasms (MPNs), present in >95% of cases of polycythemia vera (PV) and ∼50% of essential thrombocythemia (ET) and myelofibrosis (MF).1⇓⇓-4 It is usually the sole identifiable driver mutation in MPNs5 and was recently also identified as a driver of age-related clonal hemopoiesis in healthy individuals.6⇓⇓-9 In order to investigate the preclinical clonal evolution of MPNs, we identified 12 individuals with a JAK2 V617F mutant MPN, who 4.6 to 15.2 years previously (median 10.2 years) had also donated blood to register with the Cyprus Bone Marrow Donor Registry at the Karaiskakio Foundation
Description
Keywords
32 Biomedical and Clinical Sciences, 3201 Cardiovascular Medicine and Haematology, Rare Diseases, Hematology, Cancer
Journal Title
Blood Advances
Conference Name
Journal ISSN
2473-9529
2473-9537
2473-9537
Volume Title
1
Publisher
BMJ
Publisher DOI
Sponsorship
Wellcome Trust (100678/Z/12/Z)
Academy of Medical Sciences (Unknown)
Medical Research Council (MC_PC_12009)
Cancer Research UK (23015)
Academy of Medical Sciences (Unknown)
Medical Research Council (MC_PC_12009)
Cancer Research UK (23015)
This work was supported by the Wellcome Trust Sanger Institute (WT098051). T. McKerrell is funded by a Wellcome Trust Clinician Scientist Fellowship (100678/Z/12/Z). G.S.V. is funded by a Wellcome Trust Senior Fellowship in Clinical Science (WT095663MA), and work in his laboratory is also funded by Cancer Research UK, Bloodwise, the Kay Kendall Leukaemia Fund, and Celgene. I.V. is supported by the Spanish Ministerio de Economía y Competitividad, Programa Ramón y Cajal.